These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 37887283)
1. Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice. Confino H; Sela Y; Epshtein Y; Malka L; Goldshtein M; Chaisson S; Lisi S; Avniel A; Monson JM; Dirbas FM Cells; 2023 Oct; 12(20):. PubMed ID: 37887283 [TBL] [Abstract][Full Text] [Related]
2. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Wang D; Jiang W; Zhu F; Mao X; Agrawal S Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749 [TBL] [Abstract][Full Text] [Related]
3. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591 [TBL] [Abstract][Full Text] [Related]
4. Subcutaneous inoculation position affects the immune environment in CT26 carcinomas. Fu X; Yang Y; Xie J; Pan X; Yang X; Du Z; Hao E Biochem Biophys Res Commun; 2019 Apr; 512(2):244-249. PubMed ID: 30879760 [TBL] [Abstract][Full Text] [Related]
5. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020 [TBL] [Abstract][Full Text] [Related]
8. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141 [TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
11. Synergy between Zhu YC; Elsheikha HM; Wang JH; Fang S; He JJ; Zhu XQ; Chen J J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725213 [TBL] [Abstract][Full Text] [Related]
12. The KRAS Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854 [TBL] [Abstract][Full Text] [Related]
13. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440 [TBL] [Abstract][Full Text] [Related]
14. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
15. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091 [TBL] [Abstract][Full Text] [Related]
16. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461 [TBL] [Abstract][Full Text] [Related]
17. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362 [TBL] [Abstract][Full Text] [Related]
18. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030 [TBL] [Abstract][Full Text] [Related]
19. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]